Login
$XAIR
$2.21 +$0.07 (3.27%) Close

Company Executives

$XAIR Management Team

Mr. Steven Lisi

Chief Executive Officer and Chairman of the Board

Age 54
Compensation $821.1K USD
Sex Male

Mr. Michael Gaul

Chief Operating Officer

Age 71
Compensation $464.9K USD
Sex Male

Mr. Robert Goodman

Interim Chief Commercial Officer

Director

Age 60
Compensation -
Sex Male

Mr. Daniel Moorhead

Principal Financial Officer

Principal Accounting Officer

Age 53
Compensation -
Sex Male

Mr. Denton Dewrell

Controller

Age 39
Compensation -
Sex Male
Directors
6
serving now
Independent
4 of 4
stated in the proxy; 2 not stated
Average tenure
6.0 years
from year joined
CEO also chairs the board
Yes
Steven A. Lisi
Director Age On board Independent Committees Other public boards 2025 pay Source
Steven A. Lisi
55 2017
8 years
Not stated None stated None stated Paid as CEO
Robert F. Carey
67 2019
6 years
Independent
audit committee
Sangamo Therapeutics, Inc. $17,025
William Forbes
64 2018
7 years
Independent
nominating committee
None stated Not stated
Yoori Lee
53 2018
7 years
Independent
compensation committee · Chair
None stated $17,025
Erick J. Lucera
58 2017
8 years
Independent
audit committee · Chair
SAB Biopharmapeutics, Inc. $17,025
Robert S. Goodman
61 2025
0 years
Not stated None stated None stated Not stated

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

3 disclosed in the proxy filed Dec 19, 2025
Robert Carey
$7,500,000
2024

Issued 494,332 warrants with a strike price of $7.586 upon signing a binding term sheet under which Mr. Carey will loan the Company $7,500,000.

With the Company Open in proxy
Steve Lisi
$2,500,000
2024

Issued 164,778 warrants with a strike price of $7.586 upon signing a binding term sheet under which Mr. Lisi will loan the Company $2,500,000.

With the Company Open in proxy
Robert Carey
$2.0 million
2025

Amended loan agreement providing $2.0 million Additional Loans from Mr. Carey and issuing Supplemental Warrants for up to 512,821 shares at $1.95; a waiver agreement reduced the 2024 Debt Warrants exercise price from $7.59 to $1.95.

With the Company Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support